X0306 4 2021-01-21 0 0001754068 Allovir, Inc. ALVR 0001457477 Hallal David C/O ALLOVIR, INC. 139 MAIN STREET, SUITE 500 CAMBRIDGE MA 02142 1 1 1 0 Chief Executive Officer Common Stock 2021-01-21 4 A 0 147000 0.00 A 2230666 D Common Stock 13420970 I See Footnote Common Stock 1120965 I See Footnote Common Stock 738153 I See Footnote Stock Option (Right to Buy) 45.04 2021-01-21 4 A 0 273000 0.00 A 2031-01-21 Common Stock 273000 273000 D The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on January 21, 2022, with the remainder vesting in twelve equal quarterly installments thereafter. Shares held by ElevateBio LLC ("ElevateBio"). The Reporting Person is the Chairman and Chief Executive Officer of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Shares held by The Hallal Family Irrevocable Trust 2012, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Shares held by Terrie A. Hallal Family Irrevocable Trust 2012, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. 25% of this option shall vest and become exercisable on January 21, 2022, with the remainder vesting in twelve equal quarterly installments thereafter. /s/ Brett Hagen, as Attorney-in-Fact 2021-01-25